Show simple item record

AuthorCalado, Maria Beatriz
Authorda Silva Santana, Crislayne Emilly
AuthorCrovella, Sergio
Available date2022-02-27T05:38:25Z
Publication Date2021
Publication NameVirusDisease
ResourceScopus
ISSN2347-3517
URIhttp://dx.doi.org/10.1007/s13337-021-00705-3
URIhttp://hdl.handle.net/10576/27409
AbstractCOVID-19 pandemic has proven to be a dramatic challenge, introducing huge clinical differences that demand extensive investigations. Severe and critical patients may present coagulopathies and microthrombi, which results in varied complications, or acute respiratory distress syndrome that leads to fatality. Although the lung to be the major site of clinical manifestations, COVID-19 has shown extrapulmonary manifestations, especially on the heart and kidney, directly linked to worse disease outcomes. According to the fast-moving of clinical description and scientific publications, the injuries in multiple organs and systemic inflammation appear to be caused by a deregulated immune response, and the NLRP3 inflammasome could be a relevant influencer in this imbalance. However, until now, the precise drivers of the pathophysiology of these injuries remain unknown. In this review, we discuss how inflammasome seems to be directly involved in the clinical profile of patients infected with SARS-CoV-2 and shed light on the mechanisms that lead to fatality.
SponsorThis research was supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazil.
Languageen
PublisherSpringer
SubjectARDS
Coagulation
IL-1b
Inflammation
NLRP3
SARS-CoV-2
TitleDo inflammasome impact COVID-19 severity?
TypeArticle Review
Pagination410-420
Issue Number3
Volume Number32
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record